GEMONIL Drug Patent Profile
✉ Email this page to a colleague
When do Gemonil patents expire, and when can generic versions of Gemonil launch?
Gemonil is a drug marketed by Abbvie and is included in one NDA.
The generic ingredient in GEMONIL is metharbital. Additional details are available on the metharbital profile page.
Summary for GEMONIL
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 32 |
Patent Applications: | 2,350 |
Formulation / Manufacturing: | see details |
DailyMed Link: | GEMONIL at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for GEMONIL
US Patents and Regulatory Information for GEMONIL
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Abbvie | GEMONIL | metharbital | TABLET;ORAL | 008322-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |